TrialHuman vaccines & immunotherapeutics2012

HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.

Gideon Goldstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.